- National Resilience announce planned expansion of Research Triangle Park (RTP) in North Carolina for fill/finish operations
- Biopharma manufacturing capacity across Resilience network is expected to reach over 200 million units by 2025.
National Resilience, the fast growing Contract Development and Manufacturing Organisation (CDMO), has announced investment in a modular facility design at their North Carolina, Research Triangle Park (RTP) biomanufacturing plant.
This is the latest in a series of announcements from Resilience who are actively investing in a global in manufacturing network that covers pre-clinical, clinical, and commercial stages. Last month the company announced $225 million investment into Cincinnati facility to increase PFS and Cartridge fill/finish capabilities.
The company aims to supply over 200 million units across its manufacturing network by 2025. This will support various types of treatments and medical conditions, including GLP-1.
“Strengthening our drug product manufacturing capacity across the Resilience network highlights our commitment to providing robust and scalable outsourcing options for our partners,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.
“As a highly experienced team already supporting a leading pharmaceutical company with their GLP-1 products, this expansion further supports Resilience’s mission to ensure adequate biomanufacturing capacity by addressing and overcoming historic manufacturing challenges throughout the industry.”
Overview of outsourcing trends 
